NRG-018 Pembrolizumab and Chemotherapy in Uterine Cancer with Ramez Eskander

About this episode

Dr. Pedro Ramirez interviews Dr. Ramez N. Eskander about the impact of pembrolizumab combined with chemotherapy on uterine cancer treatment outcomes.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ramez N. Eskander to discuss NRG-018 pembrolizumab and chemotherapy in uterine cancer. Dr. Eskander is a gynecologic oncologist who specializes in the comprehensive management of female reproductive system cancers, including ovarian, uterine, cervical, vulvar and vaginal cancer. His expertise includes diagnostic and therapeutic procedures, including minimally invasive (robotic) surgery, chemotherapy and novel drugs. Highlights: • NRG-GY018 showed that the addition of pembrolizumab to chemotherapy, followed by maintenance pembrolizumab, resulted in a 70% lower risk of disease progression or death in patients in the dMMR cohort and a 46% lower risk in the pMMR cohort than in the placebo group. • These data suggest that the incorporation of immunotherapy into the first-line treatment of advanced or recurrent endometrial cancer improves oncologic outcomes, regardless of MMR status or histologic findings. • Previous monotherapy drugs against PD-1 and PD-L1 in recurrent or metastatic pMMR endometrial cancer resulted in only modest improvement.

People in this episode

Host: Dr. Pedro Ramirez

Guest: Dr. Ramez N. Eskander

Topics covered

• uterine cancer
• immunotherapy
• oncology
• chemotherapy
• dMMR
• pMMR

Keywords

• NRG-018
• pembrolizumab
• chemotherapy
• uterine cancer
• dMMR
• pMMR
• oncologic outcomes

Mentioned in this episode

Organizations: NRG-018, pembrolizumab, chemotherapy, dMMR, pMMR, PD-1, PD-L1, endometrial cancer

More episodes of BMJ talk medicine

• Episode 1: The present: Backlash to women’s health · March 8, 2026 · 39 min
• Episode 2: The past: How Covid-19 exposed the cracks · March 8, 2026 · 43 min
• Episode 3: The future: Gender equality as a foundation for socially just health systems · March 8, 2026 · 44 min
• Predictors of SLN Mapping Failure with Diego Raimondo and Giulia Rovero · June 5, 2023 · 26 min
• Primary Survey - the highlights of June 2023 · June 2, 2023 · 31 min
• Single-cell transcriptomics sheds new light on pancreas biology and disease · June 1, 2023 · 10 min